Anhui Fengyuan Pharmaceutical operates within the Pharmaceutical preparations sector.
In addition to historical fundamental analyses, the complete report available to purchase compares Anhui Fengyuan Pharmaceutical with three other
companies in this sector in China:
Mayinglong Pharmaceutical Group Co Ltd
sales of 2.10 billion Chinese Renmimbi [US$326.78 million]
of which 48%
was Pharmaceutical Circulation),
SSY Group Ltd
(2.02 billion Chinese Renmimbi [US$314.59 million]
of which 94%
was Intravenous Infusion Solution and Others), and
Xiangxue Pharmaceutical Co Ltd
(1.86 billion Chinese Renmimbi [US$289.25 million]
of which 34%
was Chinese Herbal Medicines).
During the year ended December of 2016, sales at
Anhui Fengyuan Pharmaceutical were 2.03 billion Chinese Renmimbi (US$316.04 million).
increase of 30.9%
versus 2015, when the company's sales were 1.55 billion Chinese Renmimbi.
Sales of Medicine Retail Circulation saw an increase
38.9% in 2016, from
920.20 million Chinese Renmimbi to 1.28 billion Chinese Renmimbi.
Not all segments of Anhui Fengyuan Pharmaceutical experienced an increase in sales in 2016:
sales of Other Operations fell 4.8% to 36.72 million Chinese Renmimbi.
(However, this segment's sales were only a very small portion of the company's overall sales).